No Data
No Data
No Data
No Data
No Data
Hyphens Pharma's Attributable Profit Narrows in 2023
Hyphens Pharma (SGX:1J5) booked a lower attributable profit to equity holders of SG$8.6 million for the year ended Dec. 31, 2023, compared with SG$11.4 million in the year-ago period, according to a f
MT NewswiresApr 9 14:16
Huationg Global CEO Increases Interest to 7.75%
Huationg Global CEO increases interest to 7.75%INSTITUTIONS were net buyers of Singapore stocks over the four trading sessions until Apr 4 inclusive, with S$49 million of net institutional inflow, as
Singapore ExchangeApr 8 09:34
Hyphens Pharma Buys Back Shares
Hyphens Pharma International (SGX:1J5) bought back 471,200 shares in the open market on Tuesday, its first purchase since the board approved a buyback program of up to 30.9 million shares last year, a
MT NewswiresApr 3 10:56
CGS-CIMB Adjusts Hyphens Pharma's Price Target to SG$0.35 From SG$0.32, Keeps at Add
02:34 AM EDT, 03/15/2024 (MT Newswires) -- CGS-CIMB Adjusts Hyphens Pharma's Price Target to SG$0.35 From SG$0.32, Keeps at Add Price (SGD): S$0.29, Change: S$0.00, Percent Change: 0.00%
MT NewswiresMar 15 14:34
Hyphens Pharma Obtains License to MC2's Psoriasis Cream
Hyphens Pharma International (SGX:1J5) obtained an exclusive license to register and commercialize MC2 Therapeutics' Wynzora plaque psoriasis cream in all 10 member countries of the Association of Sou
MT NewswiresMar 13 13:47
Hyphens Pharma Licenses Wynzora® Cream for ASEAN Countries From MC2 Therapeutics
Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading...
PR NewswireMar 12 18:12
No Data
No Data